T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research

T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research
⏱️ Reading time: 5 min read

The Ministry of Higher Education, Science, Research and Innovation (MHESI), Mahidol University, Betagro Public Company Limited, and New Zealand-based biotechnology firm NZeno Limited announced a strategic partnership on November 17, 2026, to establish the T-Xeno Hub and advance pig-to-human xenotransplantation research in Thailand. The initiative includes the formation of a joint venture, MU BioGro Co., Ltd., aimed at developing genetically modified pigs in designated pathogen-free facilities to position Thailand as ASEAN’s first cross-species organ transplantation center.

Deep Tech Strategy and Health Security

The collaboration operates under the MHESI Flagship policy framework, specifically aligned with the SIAM MEDICA pillar, which focuses on building excellence in medicine, scientific wellness, medical devices, and Advanced Therapy Medicinal Products (ATMP). By uniting academic institutions with domestic and international industry partners, the ministry aims to transition Thailand from a technology buyer into an independent developer of deep technology (Deep Tech).

T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research
T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research

Prof. Dr. Yodchanan Wongsawat, Deputy Prime Minister and Minister of Higher Education, Science, Research and Innovation, stated that health security serves as an economic foundation that reduces state budget burdens and enhances national competitiveness. He noted that the ministry is elevating Thai universities to serve as a Mastery Platform at the core of a broader ecosystem, connecting advanced scientific research to practical applications that drive the nation’s Wellness Economy.

Addressing Organ Shortages and Healthcare Costs

Thailand’s public health system faces severe organ donor shortages, with over 110,000 chronic kidney disease patients nationwide. According to 2024 figures, while approximately 23,000 patients met the criteria for a kidney transplant, only 989 received one, resulting in wait times exceeding five years and high mortality rates among waitlisted patients. Furthermore, renal replacement therapy under the Universal Coverage Scheme costs the public health system approximately 36,678 million baht annually.

T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research
T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research

Prof. Piyamitr Sritara, MD, President of Mahidol University, explained that the Thailand Xenotransplantation Hub (T-Xeno Hub) reflects the university’s Real World Impact vision by uniting the Faculty of Medicine Ramathibodi Hospital, the Faculty of Medicine Siriraj Hospital, and the Faculty of Veterinary Science, which brings over 16 years of expertise in animal cloning. The first phase spans 18 months and targets elevating technology readiness from TRL 4 to TRL 5 through the development of Designated Pathogen-Free (DPF) genetically modified pigs.

To bridge laboratory research with industrial production and clinical applications, Mahidol University and Betagro have established MU BioGro Co., Ltd. as a dedicated commercialization mechanism. Prof. Piyamitr emphasized that this Triple Helix collaboration between government, academia, and private industry will expand alternative organ sources and lower long-term healthcare expenditures.

Industrial Infrastructure and International Biotech Transfer

Betagro Public Company Limited is contributing 59 years of agro-industrial experience, including expertise in Specific Pathogen-Free (SPF) livestock farming and biosecurity management, to build the required research infrastructure. Vasit Taepaisitphongse, Chief Executive Officer of Betagro Public Company Limited, stated that the company is co-developing a DPF medical-grade pig production center at Mahidol University’s Kanchanaburi Campus, scheduled for completion within 18 months. He added that the facility reflects Betagro’s expansion from food security toward sustainable life solutions through strict environmental control and pathogen surveillance.

T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research
T-Xeno Hub Launches in Thailand for Pig-to-Human Kidney Research

Concurrently, New Zealand’s NZeno Limited is providing specialized biotechnology transfer and supplying a Medical-grade Cell Line to serve as the foundation for developing genetically modified pigs. Peter Lai, Chief Executive Officer of NZeno Limited, stated that the company is transferring its established DPF pig breeding and genetic modification protocols from New Zealand to build local research capabilities and establish strict biosecurity assessments for future human clinical trials.

#TXenoHub #Xenotransplantation #MahidolUniversity #Betagro #NZeno #MUBioGro #MHESI #WellnessEconomy #DeepTech #MedicalInnovation

Related Posts